Impact of Systemic Anti-Her2 Treatment on Overall Survival in Patients With Brain Metastases From Her2-overexpressing Breast Cancer

被引：1
|
作者：
Bartsch, R. [1 ,2 ]
Berghoff, A. [1 ,2 ]
Pluschnig, U. [1 ,2 ]
Bago-Horvath, Z. [3 ]
Dubsky, P. [4 ]
Rottenfusser, A. [5 ]
Gnant, M.
Mader, R. [1 ,2 ,4 ]
Zielinski, C. C. [1 ,2 ]
Steger, G. G. [1 ,2 ]
机构：
[1] Med Univ Vienna, Dept Med 1, Vienna, Austria
[2] Med Univ Vienna, Ctr Canc, Vienna, Austria
[3] Med Univ Vienna, Dept Pathol, Vienna, Austria
[4] Med Univ Vienna, Dept Surg, Vienna, Austria
[5] Med Univ Vienna, Dept Radiotherapy, Vienna, Austria
来源：
EUROPEAN JOURNAL OF CANCER | 2011年 / 47卷
关键词：
D O I：
10.1016/S0959-8049(11)71503-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S348 / S348
页数：1
相关论文
共 50 条
  • [41] The incidence and outcomes of brain metastases in HER2-positive metastatic breast cancer with the advent of modern anti-HER2 therapies
    Shachar, S. Strulov
    Deal, A. M.
    Vaz-Luis, I.
    Dees, E. C.
    Carey, L. A.
    Hassett, M. J.
    Garrett, A. L.
    Benbow, J. M.
    Hughes, M. E.
    Mounsey, L.
    Lin, N.
    Anders, C. K.
    CANCER RESEARCH, 2017, 77
  • [42] Anti-HER2 Therapy in Elderly Breast Cancer Patients
    Sawaki, Masataka
    REVIEWS ON RECENT CLINICAL TRIALS, 2014, 9 (04) : 263 - 266
  • [43] Survival benefit of anti-HER2 therapy after whole-brain radiotherapy in HER2-positive breast cancer patients with brain metastasis
    Qian Zhang
    Jian Chen
    Xiaoli Yu
    Gang Cai
    Zhaozhi Yang
    Lu Cao
    Chaosu Hu
    Xiaomao Guo
    Jing Sun
    Jiayi Chen
    Breast Cancer, 2016, 23 : 732 - 739
  • [44] Correlation of molecular and clinically distinct phenotypes in HER2-overexpressing breast cancer (HER2+BC) with estrogen receptor status (ER) status: Implications for anti-HER2 therapy.
    Loi, S.
    Haibe-Kains, B.
    Brown, D. N.
    Metallo, J.
    Huan, L. X.
    Desmedt, C.
    Pusztai, L.
    Piccart, M.
    Esteva, F. J.
    Sotiriou, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [45] Survival benefit of anti-HER2 therapy after whole-brain radiotherapy in HER2-positive breast cancer patients with brain metastasis
    Zhang, Qian
    Chen, Jian
    Yu, Xiaoli
    Cai, Gang
    Yang, Zhaozhi
    Cao, Lu
    Hu, Chaosu
    Guo, Xiaomao
    Sun, Jing
    Chen, Jiayi
    BREAST CANCER, 2016, 23 (05) : 732 - 739
  • [46] Survival benefits from lapatinib therapy in women with HER2-overexpressing breast cancer: a systematic review
    Yip, Adrian Yun-San
    Tse, Lap-Ah
    Ong, Eleanor Yuen-Yuen
    Chow, Louis Wing-Cheong
    ANTI-CANCER DRUGS, 2010, 21 (05) : 487 - 493
  • [47] The role of HER2-targeted therapies in women with HER2-overexpressing metastatic breast cancer
    Dent, S.
    Verma, Sh.
    Latreille, J.
    Rayson, D.
    Clemons, M.
    Mackey, J.
    Verma, Su
    Lemieux, J.
    Provencher, L.
    Chia, S.
    Wang, B.
    Pritchard, K.
    CURRENT ONCOLOGY, 2009, 16 (04) : 235 - 245
  • [48] The effects of HER2 monoclonal antibody in women with HER2-overexpressing metastatic breast cancer
    Boer R.
    Breast Cancer Research, 1 (1)
  • [49] Analysis of HER2 expression changes from breast primary to brain metastases including HER2 Low and impact on overall survival
    Pereslete, Alyssa
    Hughes, Melissa
    Patterson, Alyssa
    Files, Janet
    Nguyen, Kyleen
    Buckley, Lauren
    Patel, Ashka
    Moore, Abigail
    Winer, Eric
    Li, Tianyu
    Tolaney, Sara
    Lin, Nancy
    Sammons, Sarah
    CANCER RESEARCH, 2024, 84 (09)
  • [50] Analysis of HER2 expression changes from breast primary to brain metastases and the impact of HER2-low expression on overall survival
    Pereslete, Alyssa M.
    Hughes, Melissa E.
    Martin, Alyssa R.
    Files, Janet
    Nguyen, Kyleen
    Buckley, Lauren
    Patel, Ashka
    Moore, Abigail
    Winer, Eric P.
    Dillon, Deborah
    Li, Tianyu
    Tolaney, Sara M.
    Lin, Nancy U.
    Sammons, Sarah L.
    NEURO-ONCOLOGY, 2024, 27 (01) : 184 - 194
12345